Targeting multiple key signaling pathways in melanoma using leelamine.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Melanoma exhibits high drug resistance, often developing resistance to single-target agents.
• Constitutive activation of phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and STAT3 pathways is common in melanoma (50-70%).

Purpose of the Study:

• To identify a novel therapeutic agent capable of simultaneously inhibiting PI3K, MAPK, and STAT3 pathways in melanoma.
• To investigate the efficacy and mechanism of action of leelamine, a natural product identified from library screening.

Main Methods:

• Screening of a natural product library to identify inhibitors of PI3K, MAPK, and STAT3 pathways.
• In vitro assessment of leelamine's effects on melanoma cell survival, proliferation, and apoptosis.
• In vivo evaluation of leelamine's efficacy in xenografted melanoma models, assessing tumor growth, body weight, and organ function markers.

Main Results:

• Leelamine demonstrated selective toxicity towards melanoma cells (4.5-fold greater efficacy than normal cells) with IC(50) values of 2 μmol/L and 9.3 μmol/L, respectively.
• Leelamine inhibited melanoma cell proliferation by 40-80% at 2.5 μmol/L and induced 600% apoptosis with prolonged exposure.
• In vivo, leelamine significantly inhibited xenografted melanoma tumor growth by 60% without adverse effects on animal physiology.

Conclusions:

• Leelamine represents a promising multi-targeted agent for melanoma treatment, effectively inhibiting key oncogenic pathways.
• The novel mechanism of action involves disrupting cholesterol transport, leading to reduced proliferation, increased apoptosis, and decreased tumor vascularization.
• Leelamine offers a potential strategy to overcome drug resistance in melanoma by simultaneously targeting multiple critical signaling cascades.